Vimarsana
Biggest News Aggregation in the World

Page 25 - Dave Fredrickson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dave Fredrickson Today - Breaking & Trending Today

LYNPARZA® (olaparib) reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patie - Vimarsana News

LYNPARZA® (olaparib) reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patie

First medicine targeting BRCA mutations to show clinical benefit in adjuvant settingWILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced results from the OlympiA Phase III trial showed LYNPARZA® (olaparib) demonstrated a statistically significa...

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza reduced recurrence risk in breast cancer - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza reduced recurrence risk in breast cancer

Investegate announcements from AstraZeneca PLC, Lynparza reduced recurrence risk in breast cancer

LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo - Vimarsana News

LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo

First Medicine Specifically Targeting BRCA Mutations to Demonstrate Statistically Significant Improvement in Invasive Disease-Free Survival in Adjuvant Setting Following Definitive Local Treatment and Neoadjuvant or Adjuvant ChemotherapyKENILWORTH, N.J.--(BUSINESS WIRE)--$MRK #MRK--AstraZeneca and Merck (NYSE: MRK),...

IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Lung Cancer With 43% Of Patients Surviving Five Years - Vimarsana News

IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Lung Cancer With 43% Of Patients Surviving Five Years

Long-term data from PACIFIC Phase III trial at ASCO showed 33% of patients remained progression-free at five years Longest-ever survival reported in a Phase III immunotherapy trial in this setting ...

Imfinzi demonstrated unprecedented survival in unresectable, Stage III lung cancer with 43% of patients surviving five years - Vimarsana News

Imfinzi demonstrated unprecedented survival in unresectable, Stage III lung cancer with 43% of patients surviving five years

Date Time Share Imfinzi demonstrated unprecedented survival in unresectable, Stage III lung cancer with 43% of patients surviving five years Updated results from the positive PACIFIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit at five years in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed following concurrent chemoradiation therapy (CRT). Lung cancer is the leading cause of cancer death accounting for about one-fif...